264 related articles for article (PubMed ID: 36232430)
1. Biological Treatments for Pediatric Psoriasis: State of the Art and Future Perspectives.
Diotallevi F; Simonetti O; Rizzetto G; Molinelli E; Radi G; Offidani A
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232430
[TBL] [Abstract][Full Text] [Related]
2. Pediatric Psoriasis: From New Insights into Pathogenesis to Updates on Treatment.
Kim HO; Kang SY; Kim JC; Park CW; Chung BY
Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440145
[TBL] [Abstract][Full Text] [Related]
3. Pediatric Psoriasis.
Relvas M; Torres T
Am J Clin Dermatol; 2017 Dec; 18(6):797-811. PubMed ID: 28540590
[TBL] [Abstract][Full Text] [Related]
4. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities.
Bronckers IM; Paller AS; van Geel MJ; van de Kerkhof PC; Seyger MM
Paediatr Drugs; 2015 Oct; 17(5):373-84. PubMed ID: 26072040
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review.
Kamata M; Tada Y
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32121574
[TBL] [Abstract][Full Text] [Related]
6. Concept of Remission in Chronic Plaque Psoriasis.
Gisondi P; Di Mercurio M; Idolazzi L; Girolomoni G
J Rheumatol Suppl; 2015 Nov; 93():57-60. PubMed ID: 26523059
[TBL] [Abstract][Full Text] [Related]
7. Biologics in pediatric psoriasis.
Wang WM; Jin HZ
J Dermatol; 2023 Apr; 50(4):415-421. PubMed ID: 36651087
[TBL] [Abstract][Full Text] [Related]
8. Tailored biological treatment for patients with moderate-to-severe psoriasis.
Maurelli M; Gisondi P; Girolomoni G
Expert Rev Clin Immunol; 2023 Jan; 19(1):37-43. PubMed ID: 36300752
[TBL] [Abstract][Full Text] [Related]
9. Non-immune functions of inflammatory cytokines targeted by anti-psoriatic biologics: a review.
Lee TL; Tsai TF
Inflamm Res; 2022 Feb; 71(2):157-168. PubMed ID: 34981130
[TBL] [Abstract][Full Text] [Related]
10. Real-World Claims Analyses of Comorbidity Burden, Treatment Pattern, Healthcare Resource Utilization, and Costs in Pediatric Psoriasis.
Edson-Heredia E; Anderson S; Guo J; Zhu B; Malatestinic WN; Wine-Lee L; Swanson E
Adv Ther; 2021 Jul; 38(7):3948-3961. PubMed ID: 34091866
[TBL] [Abstract][Full Text] [Related]
11. Psoriasis in Children: A Review.
; Balato A; Scalvenzi M; Cirillo T; Gallo L; Ayala F; Balato N
Curr Pediatr Rev; 2015; 11(1):10-26. PubMed ID: 25938378
[TBL] [Abstract][Full Text] [Related]
12. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry.
Strober B; Karki C; Mason M; Guo N; Holmgren SH; Greenberg JD; Lebwohl M
J Am Acad Dermatol; 2018 Feb; 78(2):323-332. PubMed ID: 29051036
[TBL] [Abstract][Full Text] [Related]
13. Systemic Treatment of Pediatric Psoriasis: A Review.
Napolitano M; Megna M; Balato A; Ayala F; Lembo S; Villani A; Balato N
Dermatol Ther (Heidelb); 2016 Jun; 6(2):125-42. PubMed ID: 27085539
[TBL] [Abstract][Full Text] [Related]
14. Pediatric psoriasis: Understanding pathological conditions and advances in treatment.
Morita A; Saeki H
J Dermatol; 2024 Feb; 51(2):185-195. PubMed ID: 38105636
[TBL] [Abstract][Full Text] [Related]
15. [Long-term control of psoriasis is necessary].
Sánchez Carazo JL; Martínez Casimiro L; Alegre de Miguel V
Actas Dermosifiliogr; 2008 Jan; 99 Suppl 1():29-36. PubMed ID: 18341851
[TBL] [Abstract][Full Text] [Related]
16. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients.
Menter A; Cordoro KM; Davis DMR; Kroshinsky D; Paller AS; Armstrong AW; Connor C; Elewski BE; Gelfand JM; Gordon KB; Gottlieb AB; Kaplan DH; Kavanaugh A; Kiselica M; Kivelevitch D; Korman NJ; Lebwohl M; Leonardi CL; Lichten J; Lim HW; Mehta NN; Parra SL; Pathy AL; Farley Prater EA; Rupani RN; Siegel M; Stoff B; Strober BE; Wong EB; Wu JJ; Hariharan V; Elmets CA
J Am Acad Dermatol; 2020 Jan; 82(1):161-201. PubMed ID: 31703821
[TBL] [Abstract][Full Text] [Related]
17. Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use.
Takeshita J; Gelfand JM; Li P; Pinto L; Yu X; Rao P; Viswanathan HN; Doshi JA
J Invest Dermatol; 2015 Dec; 135(12):2955-2963. PubMed ID: 26214380
[TBL] [Abstract][Full Text] [Related]
18. Use of biologic agents in pediatric psoriasis.
Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
[TBL] [Abstract][Full Text] [Related]
19. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register.
Iskandar IY; Ashcroft DM; Warren RB; Yiu ZZ; McElhone K; Lunt M; Barker JN; Burden AD; Ormerod AD; Reynolds NJ; Smith CH; Griffiths CE
Br J Dermatol; 2015 Aug; 173(2):510-8. PubMed ID: 25989336
[TBL] [Abstract][Full Text] [Related]
20. Disease and treatment burden of psoriasis: examining the impact of biologics.
Raval K; Lofland JH; Waters H; Piech CT
J Drugs Dermatol; 2011 Feb; 10(2):189-96. PubMed ID: 21283925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
